Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.84 SEK | -1.51% | -2.00% | -32.12% |
05-06 | Sweden's Iconovo to Receive Chinese Patent for ICOres Inhaler | MT |
05-06 | Iconovo AB Receives Patent Protection for Icores in China | CI |
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- One of the major weak points of the company is its financial situation.
- Based on current prices, the company has particularly high valuation levels.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-32.12% | 11.52M | - | ||
+9.48% | 27.43B | B+ | ||
-28.65% | 3.18B | B- | ||
-16.08% | 2.53B | C+ | ||
+19.05% | 2.49B | - | A- | |
+11.11% | 2.16B | B | ||
-4.24% | 2.03B | - | ||
+1.69% | 1.31B | - | ||
+29.73% | 1.29B | C | ||
+8.01% | 1.17B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- ICO Stock
- Ratings Iconovo AB